Immune-Onc scores $73m

Palo Alto, California-based Immune-Onc, a cancer immunotherapy company, has secured $73 million in Series B1 and B2 financing.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this